Steven Cohen's ENGN Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 173,391 shares of enGene Therapeutics Inc. (ENGN) worth $1.18 M, representing 0.00% of the portfolio. First purchased in 2024-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in ENGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 619,100 shares. Largest reduction occurred in Q4 2025, reducing 646,602 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's enGene Therapeutics (ENGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly enGene Therapeutics (ENGN) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -388,406 | Reduce 69.14% | 173,391 | $6.81 |
| Q4 2025 | -646,602 | Reduce 53.51% | 561,797 | $9.03 |
| Q3 2025 | +100 | Add 0.01% | 1.21 M | $6.83 |
| Q2 2025 | -32,889 | Reduce 2.65% | 1.21 M | $3.64 |
| Q1 2025 | +16,391 | Add 1.34% | 1.24 M | $4.48 |
| Q4 2024 | +561,797 | Add 84.74% | 1.22 M | $6.65 |
| Q3 2024 | +619,100 | Add 1410.25% | 663,000 | $6.60 |
| Q2 2024 | -138,686 | Reduce 75.96% | 43,900 | $9.43 |
| Q1 2024 | +182,586 | New Buy | 182,586 | $16.95 |
Steven Cohen's enGene Therapeutics Investment FAQs
Steven Cohen first purchased enGene Therapeutics Inc. (ENGN) in Q1 2024, acquiring 182,586 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held enGene Therapeutics Inc. (ENGN) for 9 quarters since Q1 2024.
Steven Cohen's largest addition to enGene Therapeutics Inc. (ENGN) was in Q3 2024, adding 663,000 shares worth $4.38 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 173,391 shares of enGene Therapeutics Inc. (ENGN), valued at approximately $1.18 M.
As of the Q1 2026 filing, enGene Therapeutics Inc. (ENGN) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in enGene Therapeutics Inc. (ENGN) was 1,241,188 shares, as reported at the end of Q1 2025.